Officials fret over highly infectious BA.5 as national COVID-19 hospitalizations tick upward SCOOP: Eisai closing oncology R&D wing H3 Biomedicine for good The top 10 generic drug makers by 2021 revenue GE Healthcare to retain its household corporate name in 2023 spinoff Personalized cancer therapy biotech PACT Pharma lets go of nearly 100 staffers CMS to raise hospital payments to buy N95 masks, proposes 2.7% pay hike for facilities With $453M in realized pay in 2021, Regeneron's Schleifer was biopharma's best-paid CEO: Stat FDA clears Werfen system to rapidly test for critical bleeding Biotech earnings arrive after dreadful 6 months, but upcoming readouts offer hope to analysts Everything to know about the new crisis hotline, 988 From joint manufacturing to 'hub-and-spoke' localization, pharma's supply chain future will be a team effort: report Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus FDA OKs wearable neurostimulator from DyAnsys to treat pain from diabetic nerve damage Featured Story | By Dave Muoio New COVID-19 admissions numbers have been steadily increasing since early April and have doubled since early May, according to the CDC. read more |
| |
|---|
|
Top Stories By Max Bayer Japanese Big Pharma Eisai is shutting down its U.S.-based oncology R&D wing, H3 Biomedicine, saying the operation was "complete." As a result, the company is laying off 88 staffers. read more By Kevin Dunleavy,Zoey Becker,Fraiser Kansteiner,Angus Liu,Eric Sagonowsky Many producers of generic drugs have struggled to achieve growth in recent years due to pricing pressures. But there are promising signs that the industry is ready for an uptick, and they were evident in 2021 as eight of the top 10 companies by generics sales realized growth. read more By Conor Hale General Electric took another step forward in its plan to split up its businesses among a trio of independent, publicly traded companies. It has set out a road map into early 2024 and announced the brand names of its new scions focused on medical products, aviation and energy. read more By Max Bayer,Annalee Armstrong PACT Pharma has let go of 94 employees, leaving remaining staff to work on two clinical stage assets in immuno-oncology, according to a state workforce report in California. read more By Robert King CMS is proposing to offer enhanced Medicare payments to hospitals for buying domestically manufactured N95 masks in an attempt to avert supply chain shortages previously felt during the pandemic. read more By Angus Liu People often pay much attention to pay packages when they are granted. But when it comes to total realized pay, Regeneron CEO took home $453 million in 2021, making him the highest-paid CEO in biopharma or healthcare in general, according to Stat. read more By Andrea Park A new system from Werfen aims to conduct hemostasis tests at the point of care and return results as rapidly as possible, speeding up the process of identifying and beginning to treat cases of critical bleeding. read more By James Waldron With signs that biotech’s nosedive may be starting to level off, will the sector’s big players use their second-quarter earnings results to point to green shoots? read more By Anastassia Gliadkovskaya The hotline, whose existing number will remain in operation, will expand to help callers more broadly in emotional distress. read more By Fraiser Kansteiner Pharmaceutical supply chains have proven remarkably resilient during the COVID-19 pandemic. Still, that’s not to say drugmakers’ supply chains have made it through the past two-and-a-half years unscathed. Companies have reported difficulties getting their hands on raw materials and consumables, and at times they've had to compete with COVID-19 vaccine manufacturers for those same resources. read more By Annalee Armstrong Sanofi is letting go of a genetic kidney disease therapy under development with Regulus Therapeutics after getting a peak at an interim analysis. Development will be shut down for the anti-microRNA 21 oligonucleotide lademirsen, which was being tested in patients with a genetic disease called Alport syndrome. read more By Andrea Park As the opioid crisis rages on, the FDA has ramped up reviews of tech-based alternatives to pain relief. read more Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 